SEC Form 4 · accession 0001209191-15-064642

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP\Chief Commercial Officer

Period of report

Aug 5, 2015

Accepted (ET)

Aug 7, 2015 · 4:23 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Aug 5, 2015	M	11,328	$45.11	A	138,843	D
Common Stock	Aug 5, 2015	M	8,500	$77.31	A	147,343	D
Common Stock^F2,F3	Aug 5, 2015	S	4,200	$140.51	D	143,143	D
Common Stock^F3,F4	Aug 5, 2015	S	13,328	$141.36	D	129,815	D
Common Stock^F3,F5	Aug 5, 2015	S	2,300	$142.18	D	127,515	D
Common Stock	holding	—	—		—	140	I	401(k)

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (right to buy)^F6	$45.11	Aug 5, 2015	M	11,328	D	—	Feb 4, 2023	Common Stock	11,328	33,984	D
Stock Option (right to buy)^F7	$77.31	Aug 5, 2015	M	8,500	D	—	Feb 4, 2024	Common Stock	8,500	42,500	D

F1Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
F2Open market sales reported on this line occurred at a weighted average price of $140.51(range $139.93 to $140.92).
F3Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4Open market sales reported on this line occurred at a weighted average price of $141.36 (range $140.93 to $141.92).
F5Open market sales reported on this line occurred at a weighted average price of $142.18 (range $141.93 to $142.70).
F6The option vests in 16 quarterly installments from 02/05/2013.
F7The option vests in 16 quarterly installments from 02/05/2014.